HUMA Projected Dividend Yield

Humacyte Inc ( NASDAQ : HUMA )

Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. Co. is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). Co. has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology.

21 YEAR PERFORMANCE RESULTS